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Abstract: Percutaneous coronary revascularization has been a mainstay in the management of 
coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, 
ﬁ  rst-generation drug-eluting stents (DES), such as sirolimus-eluting (Cypher®) and paclitaxel-eluting 
stents (Taxus®), have further improved results of percutaneous coronary intervention (PCI) by improv-
ing early results and reducing the risk of restenosis. There is currently debate on the safety of these 
ﬁ  rst-generation DES, given the potential for late stent thrombosis, especially after discontinuation 
of dual antiplatelet therapy. There are well known caveats on the performance of their respective 
metallic stent platforms, delivery, and dilation systems, and polymer coatings. Second-generation 
DES, such as zotarolimus-eluting (Endeavor®) and everolimus-eluting stents (Xience V®), have 
recently become available in the USA and/or Europe. The Xience V stent holds the promise of 
superior anti-restenotic efﬁ  cacy as well as long-term safety. In addition, this stent is based on the 
Multi-link platform and delivery system. Recently available data already suggest the superiority of 
the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without 
signiﬁ  cant untoward events. Nonetheless, the number of patients studied and the follow-up duration 
are still too limited to enable deﬁ  nitive conclusions. Only indirect meta-analyses can be used to date 
to compare the Xience V with the Cypher. This systematic review tries to provide a concise and 
critical appraisal of the data in support of the Xience V everolimus-eluting stent.
Keywords: coronary artery disease, everolimus, percutaneous transluminal coronary angio-
plasty, stent
Introduction
Pre-drug-eluting stent (DES) era
Minimally invasive coronary revascularization by means of percutaneous transluminal 
angioplasty (PTCA) was introduced in the late 1970s for the management of symptoms 
of coronary artery disease (Gruntzig 1978; Gruntzig et al 1979). This technology 
has later expanded its indications, by including also unstable coronary artery disease 
(Biondi-Zoccai et al 2005a; Burzotta et al 2005) as well as patients with cardiogenic 
shock (Hochman et al 2001). Stand alone PTCA was, however, fraught with major risks 
of early abrupt closure, late restenosis due to elastic recoil, constrictive remodeling, 
and intimal hyperplasia (Fischman et al 1994; Serruys et al 1994). The development of 
bare-metal stents (BMS) enabled a reduction in the risk of early procedural complica-
tions, ﬁ  rst and foremost abrupt closure, as well as signiﬁ  cantly improving long-term 
results. However, BMS introduced a new and device-speciﬁ  c iatrogenic condition, ie, 
in-stent restenosis, mainly due to excessive neointimal proliferation within the stented 
segment.(Kasaoka et al 1998) A number of systemic treatments have been introduced 
in order to minimize complications such as in-stent neointimal hyperplasia, but all of 
them have proved unsuccessful, with the notable but still incompletely tested exception 
of systemic steroids in carefully selected patients (Versaci et al 2002).Vascular Health and Risk Management 2008:4(1) 32
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A paradigm shift has been the development of local 
anti-restenotic mechanisms; the first among these was 
brachytherapy. While clearly effective in preventing reste-
nosis at mid-term follow-up, this was, however, signiﬁ  cantly 
limited by edge effects and the risk of late thrombosis, as well 
as possibly late catch-up in restenosis (Albiero et al 2000a; 
Leon et al 2001; Waksman et al 2002).
First-generation DES era
Stemming from innovative but yet suboptimal experiences 
of local delivery of anti-restenotic radiation (Albiero et al 
2000b), the concept of a metallic stent covered with an 
anti-proliferative drug gained momentum. Despite an initial 
setback (Grube et al 2004a), this approach was soon proved 
effective in a number of pivotal trials, thus introducing the 
DES era. Speciﬁ  cally, results from the RAVEL (Morice 
et al 2002) and SIRIUS trials (Moses et al 2003) led to the 
United States Food and Drug Administration (FDA) approval 
of the sirolimus-eluting stent (Cypher®, Cordis, Miami, FL, 
USA), and data from the TAXUS I (Grube et al 2003), II 
(Colombo et al 2003), and IV (Stone et al 2004) enabled 
FDA approval of the paclitaxel-eluting stent (Taxus®, Boston 
Scientiﬁ  c, Natick, MA, USA). Both these stents were based 
on a proprietary combination of metallic platform, persistent 
biocompatible polymer, and anti-proliferative drug.
A large amount of clinical data has been generated 
focusing on these two DES: a PubMed search updated on 7 
September 2007 excluding reviews or editorials – (sirolimus 
OR paclitaxel) AND stent* AND coronary NOT (editorial[pt] 
OR review[pt]) – shows that since 1996 as many as 1034 per-
tinent studies have been published worldwide (Biondi-Zoccai 
et al 2005b). Although many trials and studies support the 
overall early and mid-term safety and efﬁ  cacy of these 
devices (Hill et al 2004), there has been considerable debate 
on their long-term safety, especially concerning the potential 
risk of late stent thrombosis (McFadden et al 2004) as well as 
late restenosis (Cosgrave et al 2007). The main problem with 
these ﬁ  rst-generation stents has been the risk of late throm-
bosis, especially after discontinuation of dual antiplatelet 
therapy (Biondi-Zoccai et al 2006b), whose recommended 
duration has been extended from 3 months (for Cypher) and 6 
months (for Taxus) to 12 months for both, at least according 
to many authorities (Iakovou et al 2005; Biondi-Zoccai et al 
2006b; Airoldi et al 2007; Grines et al 2007).
Second-generation DES era
All ﬁ  rst-generation DES decreased in a clinically and statisti-
cally signiﬁ  cant fashion angiographic and clinical restenosis 
compared with BMS, but none of them had all of the following 
desirable characteristics: a thin, biocompatible (and possibly 
bioabsorbable) polymer, optimal ﬂ  exibility, conformability, 
radiopacity, deliverability and freedom from structural frac-
tures, low late loss, and freedom from hypersensitivity reac-
tions or late thrombotic risk (Hiatt et al 2002; Biondi-Zoccai 
et al 2005c, 2007). Moreover, competing medical companies 
are striving to exploit the booming DES market. A second 
generation of DES has just been developed, and is currently 
being introduced in clinical practice in Europe and elsewhere, 
albeit to a lesser extent in the USA. The ﬁ  rst of these devices 
is the Endeavor® zotarolimus-eluting stent (Medtronic, Min-
neapolis, MN, USA), which was tested in the ENDEAVOR I 
and II trials, showing very few late thromboses and adverse 
event rates in comparison with the respective BMS (the 
remarkably effective Driver® [Medtronic]) (Meredith et al 
2005; Fajadet et al 2006, 2007). Indeed, the currently avail-
able Endeavor stent is based on a phosphorylcholine polymer 
coating, zotarolimus (formerly ABT-578) and the cobalt-based 
alloy Driver platform. Despite such promising data, the 
recent ENDEAVOR III trial has failed to prove non-inferior-
ity of the Endeavor in comparison with the Cypher in terms 
of late loss and binary restenosis, suggesting that the latter 
device should be used when thrombosis risk is not major and 
restenosis needs to be effectively minimized (Kandzari et al 
2006). Conversely, preliminary data from the 1500-patient 
ENDEAVOR IV trial comparing Endeavor vs Taxus have 
shown similar rates of target vessel failure between these two 
devices, and have thus enabled FDA approval of the Endeavor 
stent (Leon 2007).
The other second-generation DES, already approved in 
Europe and elsewhere but still awaiting FDA approval, is the 
Xience V® everolimus-eluting stent (Abbott Laboratories, 
Abbott Park, IL, USA) (Table 1). The present review aims 
to summarize basic and clinical evidence available for this 
device designed for the percutaneous treatment of coronary 
artery disease. This updated overview exploits a systematic 
highly sensitive PubMed search strategy: (everolimus OR 
xience OR promus) AND stent* (updated August 2007). 
In addition, online databases were checked for unpublished 
data (Beijk and Piek 2007; Biondi-Zoccai et al 2004).
Design and pharmacology of the 
Xience V stent and preclinical data
Platform
The platform of the Xience V stent is a L-605 cobalt chro-
mium (CoCr) balloon expandable stent remarkably similar 
to its successful BMS equivalent, the Multi-Link Vision® Vascular Health and Risk Management 2008:4(1) 33
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(Abbott Laboratories), whose main characteristics are low 
strut thickness, high ﬂ  exibility and deliverability, acceptable 
compliance, recoil and risk of plaque prolapse, and overall 
good radiopacity (Hagemeister et al 2005; Tanimoto et al 
2007). The performance of the Multi-Link Vision has already 
been proved in clinical practice, and this stent is among the 
most commonly used worldwide (Kaiser et al 2005; Ortolani 
et al 2007; Xu et al 2007).
Everolimus
Everolimus (Certican®, Novartis, Basel, Switzerland) is an 
analogue of sirolimus and it has a useful role in the pre-
vention of allograft rejection after organ transplantation. 
With its anti-proliferative and immunosuppressive actions, 
the everolimus-FKBP12 complex interferes with FRAP 
(FKBP12-rapamycin associated protein), a regulatory protein 
that controls, through the phosphorylation of p70 S6 kinase 
and 4E-BP1, cell metabolism and proliferation (Carter 2004). 
Consequentially, FRAP inhibition arrests cell cycle at the late 
G1 stage (Kahan et al 1999; Grube and Buellesfeld 2004b). 
Everolimus absorbs to local tissue rapidly and possesses 
longer cellular residence time and activity. With its potent 
suppression of reactive neointimal ingrowth, this drug has 
been shown to signiﬁ  cantly reduce of neointimal proliferation 
(Eisen et al 2003; Grube and Buellesfeld 2004a; Carter et al 
2006; Waksman et al 2006). This molecule is thus an ideal 
agent for the development of a second generation DES.
Moreover, and most recently, other unique properties of 
everolimus have been reported in an animal atherosclerotic 
model of coronary stenting. Speciﬁ  cally, Verheye et al have 
shown that stent-based delivery of everolimus selectively 
cleared macrophages in rabbit atherosclerotic plaques by 
autophagy, an mTOR inhibition-dependent and novel mecha-
nism to induce cell death in mammalian cells (Verheye et al 
2007). These features would make a device incorporating 
everolimus an ideal instrument to tackle vulnerable athero-
sclerotic plaques not yet signiﬁ  cantly stenotic but yet prone 
to rupture and thrombosis (Martinet et al 2007a, b).
Polymer
Polymer coating in the Xience V stent is formed by two layers: 
a primer and a drug reservoir, and also by two polymers: an 
acrylic polymer and a ﬂ  uoro polymer (Carter et al 2006). The 
layer of everolimus-polymer matrix with a thickness of 5–6 
microns is applied to the surface of the stent and is loaded 
with 100 µg of everolimus per cm2 of stent surface area with 
no top coat polymer layer (Serruys et al 2005). The ﬁ  rst 
25% of stent drug is released during the ﬁ  rst day after stent 
implantation, leading to 75% release during the ﬁ  rst month, 
and all drug is released within 4 months, with a minimal 
everolimus systemic level. Overall, the polymer appears 
highly biocompatible, yet falling short of the other desirable 
property of being bioabsorbable (Carter et al 2006).
Of interest, coating thickness appears less for the Xience 
V (5.3 microns) than for Cypher (7.2 microns) or Taxus 
(15.6 microns).
Clinical efﬁ  cacy studies
on the Xience V stent
SPIRIT I trial
Besides the favorable results reported on the everolimus-
eluting stents manufactured by Bionsensors (Biosensors 
International, Newport Beach, CA, USA) in the FUTURE I
 (Grube et al 2004b) (Costa et al 2005) and FUTURE II 
trials,(Tsuchiya et al 2006) the SPIRIT clinical trial program 
has been the main source of clinical data on the Xience V 
stent. (Serruys et al 2005) (Tsuchida et al 2006)
The SPIRIT First-In-Man I study was a single-blind 
randomized trial performed in 9 centers between December 
2003 and April 2004 (Serruys et al 2005). Inclusion criteria 
were stable or unstable coronary disease, with the exclu-
sion of overt myocardial infarction, plus the presence of a 
single de novo coronary lesion that was 3.0 mm in diameter 
as assessed by on-line quantitative coronary angiography 
(QCA), that could be covered by an 18 mm stent, a steno-
sis of between 50%–99% of the luminal diameter, and a 
Table 1 Currently available drug-eluting stents, with respective manufacturer, stent platform, polymer coating, active drug, mechanism 
of action, and in-stent late loss (deﬁ  ned as the difference between post-procedural minimum lumen diameter and follow-up minimum 
lumen diameter, as determined by quantitative angiography)
Stent  Manufacturer  Platform  Polymer  Drug  Mechanism  In-stent late loss in ﬁ  rst-
          of action  in-man study at 6 months
Champion Bionsensors  Multi-Link  Zeta  Bioabsorbable Everolimus  Cytostatic  0.11  ± 0.23 mm (N = 27)
Cypher Cordis  BX  Velocity  Persistent  Sirolimus Cytostatic  0.16  ± 0.30 mm (N = 45)
Endeavor Medtronic  Driver  Persistent  Zotarolimus  Cytostatic  0.61  ± 0.44 mm (N = 100)
Taxus Boston  Scientiﬁ  c  Express and Liberté  Persistent  Paclitaxel  Cytostatic  0.36 ± 0.48 mm (N = 30)
Xience Abbott  Multi-Link  Vision  Persistent  Everolimus  Cytostatic  0.10  ± 0.21 mm (N = 27)Vascular Health and Risk Management 2008:4(1) 34
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Thrombolysis In Myocardial Infarction (TIMI) ﬂ  ow grade 
of 1 or more. Notably, no patient with unprotected left main, 
chronic total occlusion, bifurcation lesion, or in-stent reste-
nosis could be included. Patients were thus randomized to 
the Xience V stent vs a matching Multi-Link Vision stent. 
A single stent, 3.0 mm in diameter, 18 mm long, was used 
in the study. Double antiplatelet therapy was recommended 
for 3 months post-procedure. Follow-up was clinical, by 
QCA and by intravascular ultrasound (IVUS) at 6 months 
(Biondi-Zoccai et al 2005d; Agostoni et al 2006) The primary 
endpoint was angiographic in-stent luminal late loss (ie, the 
difference between post-procedural minimum lumen diam-
eter [MLD] and follow-up MLD, as determined by QCA). 
Secondary endpoints at 6 months and 1 year included QCA 
in-stent and in-segment late loss, binary restenosis rate, and 
percentage diameter stenosis, plus IVUS in-stent percentage 
volume obstruction.
A total of 28 patients were randomly assigned to receive 
the everolimus-eluting stent, and 32 were assigned to receive 
the bare stent. Per-treatment results were reported (27 patients 
in the everolimus group, and 29 patients in the bare stent 
group). The mean in-stent late loss, percentage of stenosis, 
and percentage of patients with 50 percent or more stenosis 
were 0.10 mm, 16%, and 0%, respectively, in the everoli-
mus group, as compared with 0.87 mm, 39%, and 25.9%, 
respectively, in the bare stent group (p   0.001 for late loss 
and diameter stenosis, p = 0.01 for restenosis) (Serruys et al 
2005; Tsuchida et al 2006). At IVUS, less neointimal hyper-
plasia was observed in the everolimus-stent group compared 
to the bare-stent group (10 ± 13 vs 38 ± 19 mm3, p   0.001) 
and similarly, signiﬁ  cantly less volume obstruction, (8.0 ± 
10.4% vs 28.1 ± 14.0%, p   0.001). Concerning clinical 
efﬁ  cacy, despite the small sample size, the SPIRIT I trial 
suggested beneﬁ  cial effects of the Xience V stent in terms 
of target vessel failure (1/26 [3.8%] vs 6/28 [21.4%] in the 
BMS group, p = 0.102). However, this difference should be 
viewed in light of the systematic angiographic follow-up and 
the inherent risk of oculo-stenotic reﬂ  ex. Three-year follow-
up data from the SPIRIT I study have just been reported 
conﬁ  rming the efﬁ  cacy and safety of the Xience V stent.
SPIRIT II trial
The SPIRIT II trial randomized 223 patients to the Xience V 
and 77 to Taxus. Inclusion criteria were a maximum of two 
lesions with diameter between 2.5 and 3.75 and length  28 
mm (Serruys et al 2006). Follow-up with QCA and IVUS 
was recommended for all subjects, as the primary end-point 
of this non-inferiority study was 6-month in-stent late loss. 
Indeed, non-inferiority was demonstrated, but data were such 
that superiority of the Xience V was demonstrated as well. 
Speciﬁ  cally, in-stent late loss was 0.12 for Xience V and 0.37 
for Taxus (p   0.001 for both superiority and non-inferiority). 
Similarly, in-stent binary restenosis occurred in 3/237 (1.3%) 
vs 3/86 (3.5%, p = 0.194), and target lesion revascularization 
in 6/223 (2.7%) vs 5/77 (6.5%, p = 0.157). In addition, cardiac 
death occurred in 0/223 vs 1/77 (1.3%, p = 0.257), myocardial 
infarction in 2/223 (0.9%) vs 2/77 (2.6%, p = 0.272), and stent 
thrombosis in 1/223 (0.5%) vs 1/77 (1.3%, p = 0.448). Target 
vessel revascularization was instead not reported.
SPIRIT III trial
Based on these premises, there were great expectations from 
the subsequent SPIRIT III trial, a quasi-pivotal study compar-
ing Xience V vs Taxus which was conducted in the US. While 
data are yet unpublished, they have already been reported at 
international congresses. A total of 1002 patients with fea-
tures similar to those enrolled in SPIRIT II were randomized 
to Xience V (n = 669) vs Taxus (n = 333). Dual antiplatelet 
therapy was continued for 6 months. The primary end-point 
was 6-month in-segment late loss, with pre-speciﬁ  ed non-
inferiority and superiority designs. Major adverse cardiovascu-
lar events at 270 days were appraised as secondary end-points. 
Six-month angiographic follow-up was completed in 77% of 
patients (n = 302 for Xience V and n = 134 for Taxus). In-
segment late loss proved signiﬁ  cantly lower in the Xience V 
group than in the Taxus group, 0.14 ± 0.41 mm vs 0.28 ± 0.48 
mm (p   0.001 for non-inferiority, p = 0.004 for superiority). 
In-stent late loss was similarly reduced: 0.16 ± 0.41 mm vs 
0.30 ± 0.53 mm. Binary restenosis was also lower with Xience 
V, occurring in 14/302 (4.7%) vs 12/134 (8.9%, p = 0.079) in-
segment and 7/302 (2.3%) vs 8/134 (5.7%, p = 0.083) in-stent. 
Intriguingly, clinically relevant reductions of end-points were 
achieved with Xience V, with target lesion revascularization 
occurring in 17/669 (2.6%) vs 17/333 (5.0%, p = 0.035), 
target vessel failure (based on target vessel revascularization) 
in 48/669 (7.2%) vs 30/333 (9.0%, p = 0.307), major adverse 
cardiovascular events (based on target lesion revasculariza-
tion) in 31/669 (4.6%) vs 30/333 (8.1%, p = 0.006), and stent 
thrombosis in 3/669 (0.5%) vs 0/333 (p = 0.555). Overall, this 
trial conﬁ  rmed the positive expectations of previous trials, 
suggesting the superiority of the Xience V stent in comparison 
with Taxus in terms of clinical efﬁ  cacy.
Intriguingly, a meta-analysis of approximately 1300 
patients from the SPIRIT II and SPIRIT III clinical trials has 
indicated that the Xience V system demonstrated superiority 
over the Taxus stent in angiographic and clinical endpoints, Vascular Health and Risk Management 2008:4(1) 35
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with an excellent safety proﬁ  le (unpublished data). The data 
for the Xience V versus the Taxus, respectively were: major 
adverse cardiovascular events (4.0% vs 8.0%, p for superi-
ority = 0.004), target lesion revascularization rate (2.4% vs 
5.1%, p for superiority = 0.01), in-stent binary restenosis 
rate (1.9% vs 4.9%, p for superiority = 0.02), and in-segment 
restenosis rate (4.1% vs 7.8%, p for superiority = 0.04).
Upcoming trials
Upcoming trials on the Xience V stent include the SPIRIT 
IV, SPIRIT V and SPIRIT WOMEN trials. Speciﬁ  cally, the 
SPIRIT IV study will evaluate the safety and efﬁ  cacy of 
this DES in comparison to the Taxus stent for the treatment 
of subjects with up to three de novo native coronary artery 
lesions, and with a maximum of two lesions per epicardial 
vessel. This randomized controlled trial will be conducted 
in the USA and include 1125 patients with coronary artery 
lesions 2.5–4.25 mm in diameter and lesion length of  28 
mm. Clinical follow-up will be at 30, 180, 270 days, and 1, 
2, 3, 4, 5 years. The SPIRIT V Clinical Evaluation will be 
a prospective, single-blind, double arm, randomized multi-
center study comparing the Xience V stent vs Taxus in the 
treatment of diabetic patients with coronary artery lesions 
(Spirit V Diabetic study), performed in parallel to a prospec-
tive, open-label, single arm registry evaluating performance 
of the Xience V stent in real life use (Spirit V Registry). This 
multicenter study will enroll approximately 300 patients in 
the Spirit V Diabetic study in a 2:1 ratio and 2700 patients 
will be enrolled in the Spirit V Registry. Patients must have 
lesions between 2.5 mm and 4.0 mm in diameter and  28 mm 
in length by visual estimation. Angiographic follow-up will 
be scheduled at 9 months only for the Spirit V Diabetic study. 
The primary end point will be in-stent late loss at 270 days. 
The Spirit V Registry will only include a clinical follow-up 
and the primary end point will be adjudicated composite rate 
of all-cause death, myocardial Infarction and target vessel 
revascularization. Finally, the SPIRIT WOMEN trial will 
be the ﬁ  rst coronary interventional device study focusing on 
females only. Details are upcoming.
Clinical safety of the Xience V stent
The safety proﬁ  le of the Xience V stent has been to date quite 
satisfactory, despite the duration of dual antiplatelet therapy 
limited to the conventional 3–6 months. Speciﬁ  cally, 3-year 
data from the SPIRIT I trial demonstrated no signiﬁ  cant 
increase in major adverse cardiac events or late stent throm-
bosis in patients treated with Xience V. Similarly favorable 
results have been reported from the SPIRIT II (one patient 
had late stent thrombosis by 6 months in each group) and 
SPIRIT III trials (stent thrombosis rates at 270 days 0.5% 
for Xience V vs 0 for Taxus). Late incomplete apposition 
(ie, stent malapposition), a phenomenon potentially associ-
ated with late stent thrombosis, was similarly uncommon with 
either Xience V or Taxus in the SPIRIT II and III trials. These 
ﬁ  ndings have enabled European approval of this device, while 
FDA approval is pending.
The total number of patients treated with Xience V and 
the overall follow-up is still too limited to draw deﬁ  nitive 
conclusions on safety, which have proved quite challenging 
with ﬁ  rst generation DES (Agostoni et al 2007). Some authors 
have purported an inverse association between late loss and 
thrombotic risk. Thus, in keeping with this hitherto unproved 
hypothesis, DES achieving a greater degree of neointimal 
hyperplasia inhibition, such as the Xience V stent, would 
be associated with an increased risk of stent thrombosis, at 
least in comparison to devices which are less aggressive on 
neointimal hyperplasia (eg, the Endeavor stent). This theory 
remains however unproven as average neointimal formation 
and stent strut endothelialization are two separate biological 
phenomena. Thus, extreme caution should be exercised when 
inputing lower risk of stent thrombosis with devices associated 
on average with more late loss (ie, neointimal proliferation). 
Most recent data from the ENDEAVOR IV trial, showing 
non-signiﬁ  cantly higher rates with the Endeavor stent vs the 
Taxus stent despite opposite trends for late loss, further call 
into question the above mentioned hypothesis (Leon 2007).
Nonetheless, in patients similar to those enrolled in the 
SPIRIT I, II and III trials, we can expect similar efﬁ  cacy and 
safety after deployment of a Xience V stent. Whether a longer 
duration of dual antiplatelet therapy is warranted in selected 
patients, remains to be clariﬁ  ed (Airoldi et al 2007).
Patient-focused perspective
Percutaneous coronary revascularization is a mainstay in 
the management of coronary artery disease. Indeed, PTCA 
with concomitant stent implantation provides symptomatic 
beneﬁ  ts in patients with stable coronary artery disease 
(Hochman et al 2006; Boden et al 2007) which are equiva-
lent to those following coronary artery bypass surgery 
(Biondi-Zoccai et al 2003), and, on top of that, prognostic 
beneﬁ  ts in selected higher risk subjects such as those with 
unstable coronary disease (Biondi-Zoccai et al 2005a; 
Erne et al 2007). However, the prognostic beneﬁ  ts in stable 
patients have been recently debated (Hochman et al 2006), 
and even symptomatic relief may not be persistent in certain 
groups of patients (Boden et al 2007). Several reasons can Vascular Health and Risk Management 2008:4(1) 36
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be advocated, but one of the most common is recurrent 
ﬂ  ow-limiting stenosis at the target coronary lesion originally 
treated with PTCA and stenting.
The issue of restenosis has thus been the focus of intensive 
research since the introduction of PTCA, and DES have come 
a long way in inhibiting in-stent neointimal hyperplasia while 
exploiting the mechanical scaffolding properties of the metal-
lic stent platform. On the other hand, DES (including Xience 
V) are not immune from adverse effects. The most fearsome 
is stent thrombosis, which if often due to improper stent 
implantation (Biondi-Zoccai et al 2006a) and/or incomplete 
endothelialization of stent struts (Biondi-Zoccai et al 2006b). 
To minimize this risk, prolonged dual antiplatelet therapy with 
aspirin and a thienopyridine (either clopidogrel or ticlopidine) 
is routinely recommended after DES implantation, from a min-
imum of 2 months (in the RAVEL trial focusing on Cypher) 
(Morice et al 2002) to a maximum of 12 months as currently 
enforced by international guidelines (Grines et al 2007).
Patients candidate for PTCA with DES implantation 
should thus be carefully screened for indications and contra-
indications to such prolonged dual oral antiplatelet therapy. 
In case of unsuitability for such aggressive antithrombotic 
therapy, other interventions, including PTCA with BMS or 
balloon-only, coronary artery bypass, or medical therapy 
should be considered and decision making individualized.
Conclusions and future perspectives
The everolimus-eluting Xience V stent is among the most 
promising of second generation drug-coated stents designed 
for the percutaneous treatment of coronary artery disease. 
Clinical efﬁ  cacy data are to date quite satisfactory, whereas 
clinical safety data are promising but yet incomplete as lim-
ited only to early and mid-term follow-up ( 12 months). If 
these promises will be fulﬁ  lled in further follow-up of com-
pleted trials and in upcoming randomized trials and registries, 
the Xience V stent will surely become a major player in the 
second-generation DES era.
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